LUCD vs. TLIS, NH, BDSX, DCTH, PROF, ARAY, CLPT, QIPT, TELA, and CVRX
Should you be buying Lucid Diagnostics stock or one of its competitors? The main competitors of Lucid Diagnostics include Talis Biomedical (TLIS), NantHealth (NH), Biodesix (BDSX), Delcath Systems (DCTH), Profound Medical (PROF), Accuray (ARAY), ClearPoint Neuro (CLPT), Quipt Home Medical (QIPT), TELA Bio (TELA), and CVRx (CVRX). These companies are all part of the "medical" sector.
Lucid Diagnostics (NASDAQ:LUCD) and Talis Biomedical (NASDAQ:TLIS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, community ranking, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.
Lucid Diagnostics has higher revenue and earnings than Talis Biomedical. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Talis Biomedical, indicating that it is currently the more affordable of the two stocks.
Lucid Diagnostics received 19 more outperform votes than Talis Biomedical when rated by MarketBeat users. Likewise, 62.22% of users gave Lucid Diagnostics an outperform vote while only 37.50% of users gave Talis Biomedical an outperform vote.
In the previous week, Lucid Diagnostics had 2 more articles in the media than Talis Biomedical. MarketBeat recorded 2 mentions for Lucid Diagnostics and 0 mentions for Talis Biomedical. Talis Biomedical's average media sentiment score of 0.00 beat Lucid Diagnostics' score of -0.67 indicating that Talis Biomedical is being referred to more favorably in the news media.
74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 43.8% of Talis Biomedical shares are owned by institutional investors. 4.8% of Lucid Diagnostics shares are owned by company insiders. Comparatively, 46.0% of Talis Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Lucid Diagnostics has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Comparatively, Talis Biomedical has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500.
Lucid Diagnostics has a net margin of -1,576.60% compared to Talis Biomedical's net margin of -5,784.73%. Talis Biomedical's return on equity of -75.40% beat Lucid Diagnostics' return on equity.
Lucid Diagnostics presently has a consensus target price of $4.33, suggesting a potential upside of 462.04%. Talis Biomedical has a consensus target price of $5.00, suggesting a potential downside of 45.36%. Given Lucid Diagnostics' stronger consensus rating and higher possible upside, research analysts clearly believe Lucid Diagnostics is more favorable than Talis Biomedical.
Summary
Lucid Diagnostics beats Talis Biomedical on 12 of the 18 factors compared between the two stocks.
Get Lucid Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LUCD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LUCD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Lucid Diagnostics Competitors List
Related Companies and Tools